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Introduction
Meconium aspiration syndrome (MAS) is a complex
disease of the newborn, and may result in considerable
respiratory morbidity. It is also the most common dis-
ease in neonatal patients treated with extracorporeal
membrane oxygenation (ECMO).1 In the past decades,
there has been a reduction in the incidence of MAS
because of advances in perinatal care.2 In a recent report,
the incidence of severe MAS (infants who were intu-
bated and mechanically ventilated with a primary diag-
nosis of MAS) was 0.43 per 1,000 live births. However,
death related to MAS in these patients was still 2.5%.2
Therefore, an effective therapy to improve outcome is
crucial in treating neonates with severe MAS.
The pathophysiology of MAS includes airway ob-
struction,3 surfactant inactivation,4,5 inflammation,6–8
and pulmonary hypertension.9,10 Successful treatment
of severe MAS relies on effective meconium removal
without inactivating or washing out surfactant, followed
with appropriate ventilatory care.
Inhibition of surfactant function in alveolar space
may be mediated by aspirated meconium, plasma pro-
teins, hemoglobin and edema fluid.11 Bolus surfactant
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therapy has been found to reduce the requirement for
ECMO, but no diminution of air leak or ventilatory
days.11 Lung lavage using diluted surfactant has recently
been shown to be an alternative to bolus therapy in
treating MAS. That has the advantage of removing
surfactant inhibitors from the alveolar space, in addi-
tion to augmenting surfactant concentration in alveolar
space.11 Good toleration and effective response were
documented in animal models12–18 and human infants
with MAS.19–23 The reported benefits of lung lavage
in MAS included removing significant amounts of
meconium and alveolar debris, and thereby improving
oxygenation and pulmonary mechanics.11
We present 3 newborns with severe MAS, including
2 who fulfilled the criteria for ECMO (oxygenation
index > 40).24 All were successfully treated by thera-
peutic lung lavage with diluted surfactant.
Case Reports
The basic characteristic data of the 3 cases are summa-
rized in Table 1. All were full-term newborn infants,
born in local obstetrics clinics or hospitals. Although
they presented with meconium-stained amniotic fluid
and non-vigorous activity at birth, none received endo-
tracheal suction in the delivery room. Two of them
(Cases 1 and 2) needed cardiopulmonary resuscitation
right after birth. They were then transferred to our
neonatal intensive care unit within 2 hours of age.
Case 1
This female baby presented with pulmonary hem-
orrhage on arrival. After endotracheal epinephrine
administration, the hemorrhage stopped. However,
hypoxia persisted even under high settings of high-
frequency oscillatory ventilation (HFOV). Chest X-ray
showed bilaterally diffuse patchy infiltration (Figure 1).
Persistent pulmonary hypertension of the newborn was
diagnosed with evidence of right-to-left shunts on
echocardiography. Thus, inhaled nitric oxide was started.
However, her condition continued to deteriorate, and
the highest oxygenation index was as high as 66.7 when
the patient was 14 hours old.
With the agreement of the baby’s father and stabi-
lization of the patient’s condition (pH > 7.25, oxygen
saturation higher than 90%, and mean blood pressure
higher than 50 mmHg), the baby received therapeu-
tic lung lavage when she was 20 hours of age accord-
ing to the protocol of the lessMAS trial.25 In brief, 
2 aliquots of lavage fluid (15 mL/kg) with diluted
surfactant (Survanta; Abbott Laboratories, North
Chicago, IL, USA) were used for lung lavage. The baby
was positioned with the chest right side down during
the first lavage, and left side down during the second
lavage. In each lavage, the diluted surfactant was
instilled into the lungs within 20 seconds. Then, posi-
tive pressure ventilation was delivered for 10 seconds.
After that, as much lavage fluid as possible was aspi-
rated within 30–40 seconds. Brief desaturation (85% to
54%) was observed when the lavage procedure was
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Table 1. Characteristics of the 3 cases
Case
1 2 3
Birth weight (g) 3,634 3,350 3,480
Gestational age (wk) 39 40 41
Sex F M M
Apgar score (1 min/5 min) 2/6 2/5 7/7
Delivery mode Cesarean section Vaginal delivery Vaginal delivery
In/Out born Out Out Out
Endotracheal suction in delivery room No No No
Persistent hypertension of newborn Yes No No
Oxygenation index when admitted 41.5 31.5 13.3
Total ventilatory days 7 3 2
Ventilatory mode (d) HFOV(3) + IMV(4) IMV(3) HFOV(1) + IMV(1)
Nasal prong CPAP (d) 4 5 2
Inhaled nitric oxide (d) 2 0 0
Inotropics (d) 5 3 0
NICU stay (d) 15 12 5
Hospital stay (d) 23 23 9
CPAP = continuous positive airway pressure; HFOV = high frequency oscillatory ventilation; IMV = intermittent mechanical ventilation; NICU = neonatal intensive
care unit.
begun, but it quickly returned to 80% as the mean air-
way pressure of HFOV increased. The second lavage
was performed 5 minutes after the first. A similar
desaturation pattern was noted (80% to 58%), but it
also quickly returned to 80%. Brief bradycardia was
observed during the second aliquot of lavage, but it
also returned to normal very soon (Figure 2).
The patient’s clinical condition improved soon after
lung lavage. Chest X-ray taken after 24 hours showed
significant improvement (Figure 1B). Table 2 summa-
rizes the changes in oxygenation index, alveolar–arterial
oxygen tension difference, heart rate and blood pres-
sure before and after lavage. Inhaled nitric oxide was
discontinued when the patient was 48 hours old, and
she was successfully extubated 7 days later. She was
discharged when she was 23 days old without respira-
tory or neurologic complications. After discharge, she
was hospitalized 4 times within the first year of life
due to respiratory tract infections.
Case 2
This male infant’s condition was very critical when 
he arrived at our neonatal intensive care unit with the
appearance of extreme hypotonia, hypoxia, hypoten-
sion, and very unstable vital signs. Profound metabolic
and respiratory acidosis (pH 6.83) was also noted 
on arrival. Diffuse haziness with patchy infiltration
and zones of hyperinflation were noted on the initial
chest X-ray (Figure 3A). The oxygenation index was
as high as 43.0.
With the agreement of the patient’s father, lung
lavage with diluted surfactant was tried to rescue his
life, even though the general condition of this patient
could not be stabilized (pH 6.84, oxygenation satura-
tion 70%, mean blood pressure 22 mmHg). The same
protocol as used in Case 1 was performed when this
patient was 2 hours old. Significant overflow of the
lavage fluid was observed during the instillation phase,
and a total of 40 mL of bloody fluid was recovered
(Table 2). Improvement in oxygenation was observed
after lavage, but his condition deteriorated 1 hour 
later, with decreased oxygenation and hypotension.
Chest X-ray revealed white-out lung (Figure 3B).
Bilateral pleural effusion was suspected, and thoraco-
centesis was performed. Pleural fluid (47 mL on right
side and 18 mL on left side, straw colored) was tapped
out, and his condition improved again soon after the
procedure.
Chest X-ray after chest tapping (Figure 3C) and
on the second day (Figure 3D) both showed signifi-
cant improvements. The patient was successfully extu-
bated 3 days after lavage, and discharged smoothly at
the age of 23 days. Although there were no respira-
tory complications in this case, mild developmental
delay was observed, and brain imaging study revealed
ventricular dilatation and periventricular leukomalacia.
Case 3
This male neonate was transferred to our hospital within
1 hour of birth. Central cyanosis, hypotonia and brady-
cardia were observed on his arrival, and we suctioned
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Figure 2. Case 1: real-time monitoring of heart rate and oxygen
saturation during lung lavage. The vertical line indicates the start
of the first lavage, and the arrow indicates the start of the second
lavage.
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Figure 1. Chest X-ray of Case 1: (A) before lavage; (B) 24 hours after lavage.
out some meconium from the patient’s trachea.
Bilateral patchy infiltration was observed on chest 
X-ray (Figure 4A). His condition deteriorated gradu-
ally in spite of adequate mechanical ventilation. The
maximal oxygenation index was 26.2.
With the parents’ agreement, lung lavage with the
same protocol as in Case 1 was performed when this
patient was stabilized at the age of 8 hours. Brief
desaturation and bradycardia were also noted during
the lavage procedures, but with rapid recovery.
Bloody fluid was recovered from endotracheal suction
(Table 2). His general condition and laboratory data
improved soon after lavage (Table 2). Chest X-ray
also demonstrated significant improvement (Figure 4B).
The patient was extubated successfully 41 hours
after lavage, and discharged 7 days later. There were
no respiratory or neurologic complications during the
first year of his life.
Discussion
Direct endotracheal suction of the aspirated meconium
right after birth in meconium-stained and non-vigorous
newborns has been suggested in neonatal resuscita-
tion programs.26,27 Unfortunately, all of our pre-
sented newborns were born in local obstetrics clinics
or hospitals without standby pediatric care, and none
received immediate endotracheal suction even though
they were all meconium-stained and non-vigorous at
birth. Therefore, there remains much room for improve-
ment in perinatal care in Taiwan. Maternal trans-
portation for high-risk and post-term pregnancies to
centers with well-trained neonatal care personnel and
high-quality facilities should be seriously considered
for the safety of pregnant women and their expected
newborns, because meconium may result in serious
complications.28,29
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Table 2. Descriptive data before and after lung lavage of the 3 cases
Case
1 2 3
Age on arrival at tertiary hospital (hr) 2 1 1
Age when BAL performed (hr) 21 3 8
Lavage fluid (out/in), mL (%) 55/108 (51) 40/99 (40) 50/102 (49)
Appearance of lavaged-out fluid Bloody, turbid Bloody, turbid Bloody, turbid
Maximum OI before lavage 66.7 43.0 26.2
Right before lung lavage
OI 34.4 39.0 20.0
A-aDO2 (mmHg) 619 457 613
HR (beats/min) 158 140 133
BP (systolic/diastolic) (mmHg) 60/46 32/29 80/21
4 hr after lung lavage
OI 11.4 39.1 8.2
A-aDO2 (mmHg) 548 571 319
HR (beats/min) 160 184 124
BP (systolic/diastolic) (mmHg) 59/48 68/50 64/40
24 hr after lung lavage
OI 9.3 9.2 2.6
A-aDO2 (mmHg) 237 389 82
HR (beats/min) 138 155 133
BP (systolic/diastolic) (mmHg) 68/51 61/44 67/42
48 hr after lung lavage
OI 8.1 4.2 Extubated
A-aDO2 (mmHg) 225 111 2.5
HR (beats/min) 154 112 134
BP (systolic/diastolic) (mmHg) 63/44 75/56 81/59
BAL = bronchoalveolar lavage; OI = oxygenation index; A-aDO2 = alveolar-arterial oxygen tension difference; HR = heart rate; BP = blood pressure.
Therapeutic lung lavage has been investigated for
treating MAS in recent years. Isotonic saline bron-
choalveolar lavage has been experimented with, reveal-
ing detrimental effects.13 Full-strength and diluted
surfactants have also been investigated as possible
lavage fluids.14–16 The total lavage volumes in these
studies have varied. Large-volume diluted surfactant
lavage seemed to show the most beneficial effects,
with improvements in gas exchange and decreases in
proinflammatory cytokines.12,17 In our 3 cases, a total
of 30 mL/kg diluted surfactant in 2 aliquots was used
to perform lung lavage. This amount was based on
the suggestion of Dargaville et al17 and Dargaville and
Copnell,25 and the clinical outcomes of our cases were
excellent. Although brief desaturation and bradycardia
were observed during lavage, there was rapid improve-
ment after the procedure was completed in Cases 1
and 3.
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Figure 4. Chest X-ray of Case 3: (A) before lavage; (B) 24 hours after lavage.
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Figure 3. Chest X-ray of Case 2: (A) before lavage; (B) 2 hours after lavage, before chest tapping; (C) 5 hours after lavage, after chest
tapping; (D) 24 hours after lavage.
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Different lavage protocols have been reported 
in recent years.19,22,28 Lejeune and Pfister reported 
a newborn infant who underwent lavage with a small
volume of diluted surfactant (Curosurf, 5 mg/mL, 
a total of 15 mL/kg, in aliquots of 2 mL), in whom
they achieved a successful result.19 Lista et al reported
8 newborn infants with MAS who underwent lung
lavage with diluted surfactant (Curosurf, 5.3 mg/mL,
a total of 15 mL/kg, in aliquots of 2.5 mL), and found
similar improvements without the lavage causing major
adverse effects.22 In addition, Hung et al reported 
11 newborns who underwent lavage with a small vol-
ume of diluted surfactant (Survanta, 10mg/mL, a total
of 20 mL, in aliquots of 2 mL), and another 9 infants
who underwent lavage with a larger volume of diluted
surfactant (Survanta, 5 mg/mL, a total of 40 mL, in
aliquots of 2 mL); they found similar benefits from the
2 treatment protocols.30 Our 3 cases underwent lavage
with large-bolus lavage volumes (15 mL/kg/dose)
with a total of only 2 aliquots. This is different from
the protocol used in other case reports, and we found
it to be safe when performed in infants with severe
MAS when the patients are stabilized before lavage.
Although several randomized controlled trials of sur-
factant lavage in MAS have been conducted,25 there
are no conclusive results yet. However, we believe there
will be evidence-based results in the near future. In
addition, some of the above reported cases received
adequate endotracheal suction in the delivery room, and
still obtained benefits from diluted surfactant lavage.
In our reported cases, only 1 (Case 2) had an unex-
pected course during and after lavage, due to the
presence of bilateral pleural effusion. Since there was
significant overflow of the lavage fluid and initial chest
X-ray showed bilateral haziness, congenital pleural
effusion was highly suspected. Also, the straw-colored
pleural effusion was quite different from the bloody
fluid recovered from therapeutic lavage. There has
been no such similar complication reported in previous
animal or human studies of diluted surfactant lung
lavage. Furthermore, the lavage procedure in Case 2
was performed when a stable condition could not be
achieved. This may have contributed to why we could
not demonstrate a similar pattern of improvement as
observed in the other 2 cases (Figure 2). The success
of treating this case relied on lung lavage to remove
meconium debris and chest tapping to remove bilateral
pleural fluid. Therefore, detailed evaluation of under-
lying pulmonary pathology and patient stabilization
before lung lavage are crucial for best outcome.
In conclusion, therapeutic lung lavage with diluted
surfactant in severe MAS may improve outcome with-
out significant adverse side effects. Before performing
lung lavage, stabilization and optimal support may
prevent unexpected results during and after lavage.
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